MaxCyte, Inc.
MXCTAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Mar 12, 2025 | BTIG | Mark Massaro | $6.00(+73%) | $3.47 | TheFly |
| Mar 13, 2024 | BTIG | Mark Massaro | $8.00(+92%) | $4.16 | StreetInsider |
| Aug 14, 2022 | BTIG | Mark Massaro | $11.00(+87%) | $5.87 | TheFly |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Craig-Hallum | maintain | Buy | Mar 25, 2026 |
| BTIG | downgrade | Buy →Neutral | Aug 11, 2025 |
| William Blair | downgrade | Outperform →Market Perform | Aug 7, 2025 |
| Stifel | maintain | Buy | Mar 12, 2025 |
| Stephens & Co. | maintain | Overweight | Apr 23, 2024 |
| Stephens & Co. | maintain | Overweight | Mar 13, 2024 |
| BTIG | maintain | Buy | Mar 13, 2024 |
| Stephens & Co. | maintain | Overweight | Oct 5, 2023 |
| Stephens & Co. | maintain | Overweight | Mar 28, 2023 |
| BTIG | maintain | Buy | Aug 15, 2022 |
| Stifel | maintain | Buy | Aug 24, 2021 |
| BTIG | maintain | Buy | Aug 24, 2021 |
| Stephens & Co. | maintain | Overweight | Aug 24, 2021 |
| William Blair | maintain | Outperform | Aug 24, 2021 |
| Cowen & Co. | maintain | Outperform | Aug 24, 2021 |
Earnings History
| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 12, 2026 | $-0.08 | $-0.09 | $7.3M | $6.5M |
| May 12, 2026 | $-0.04 | $-0.10 | $9.7M | $7.3M |
| Mar 24, 2026 | $-0.06 | $-0.08 | $7.3M | $9.1M |
| Nov 12, 2025 | $-0.12 | $-0.11 | $6.8M | $9.4M |
| Aug 6, 2025 | $-0.12 | $-0.10 | $8.5M | $10.4M |
| May 7, 2025 | $-0.10 | $-0.10 | $10.4M | $9.6M |
| Mar 11, 2025 | $-0.10 | $-0.12 | $8.7M | $9.3M |
| Nov 6, 2024 | $-0.11 | $-0.13 | $8.2M | $7.7M |
News
ROCKVILLE, Md., Oct. 28, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (NASDAQ: MXCT), a leading cell-engineering company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell therapeutics, today announced Company management will participate in three upcoming investor conferences.
MaxCyte will host its third quarter 2026 earnings conference call on November 10, 2026 MaxCyte will host its third quarter 2026 earnings conference call on November 10, 2026
ROCKVILLE, Md., Sept. 23, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (Nasdaq: MXCT), a leading cell engineering company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that it has appointed Sidharth Kapileshwar as Chief Corporate Development Officer.
ROCKVILLE, Md., Sept. 11, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (Nasdaq: MXCT), a leading cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, reported today that the Compensation Committee of the Board of Directors of MaxCyte granted inducement awards in the form of stock options to purchase an aggregate of 220,000 shares of MaxCyte's common stock and a service-based restricte…
ROCKVILLE, Md., Aug. 19, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced the launch of the CHANGE-seq-BE™ and ONE-seq-BE™ off-target nomination assays. Available through MaxCyte's SeQure™ service, these assays address a key gap in genome editing characterization by offering sensitive nominatio…
MaxCyte NASDAQ: MXCT reported second-quarter 2026 revenue of $7.3 million, down 15% from $8.5 million a year earlier, as lower license revenue, timing of instrument placements and prior-year processing assembly purchases affected results. Management said the quarter came in ahead of its expectations and represented progress toward stabilizing the business before returning to growth in the second half of the year.
MaxCyte, Inc. (MXCT) Q2 2026 Earnings Call Transcript
MaxCyte, Inc. (MXCT) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to a loss of $0.12 per share a year ago.
Reports total revenue of $7.3 million for the second quarter of 2026, including $6.5 million of core revenue and $0.8 million of SPL Program-related revenue Reiterates Full Year 2026 Guidance Repurchased approximately $5.5 million of common stock to date under the Company's $10 million share repurchase program authorized by the Board Following end of quarter, announced strategic, multi-platform technology license partnership with Genentech in July ROCKVILLE, Md., Aug. 12, 2026 (GLOBE NEWSWIRE) -…